OGX-427: Phase II started

OncoGenex said investigators at the Sarah Cannon Research Institute began the double-blind, placebo-controlled, U.S. Phase II Spruce trial to compare IV OGX-427 plus carboplatin and pemetrexed vs. placebo plus carboplatin and pemetrexed in about 155 treatment-naïve patients with advanced, non-squamous NSCLC. Patients will receive 3 loading doses of 600 mg OGX-427 within the first 9 days prior to the treatment phase, in which patients will receive 600 mg OGX-427 weekly in a 21-day cycle for 4 cycles. ...